Do you notice any improvement with cosentyx?

What Do Patients Say About Cosentyx's Effectiveness?

According to [1], a phase III trial demonstrated significant improvements in psoriatic arthritis (PsA) symptoms in patients treated with Cosentyx. At week 24, 63.3% of patients achieved ≥20% improvement in joint assessment (ACR20), and 42.5% achieved ASAS40 (Assessment of SpondyloArthritis international Society 40%). The majority (81.3%) reported moderate to complete resolution of skin symptoms.

Long-Term Efficacy and Safety [2]

Clinical trials evaluating the long-term safety and efficacy of Cosentyx in patients with PsA and psoriasis have shown that the treatment maintains its effectiveness and demonstrates a favorable safety profile over several years of follow-up.

Why Are Companies Challenging This Patent?

DrugPatentWatch.com notes that the patent for Cosentyx (secukinumab) is set to expire in [3]. Given the drug's commercial success, it is expected that companies may challenge the patent or attempt to develop biosimilar alternatives to enter the market.

Side Effects and Patient Concerns

While generally well-tolerated, Cosentyx can cause common side effects such as injection-site reactions, nasopharyngitis, and headache. Less frequently, patients may experience more serious adverse events, including hypersensitivity reactions [4].

Pricing and Alternative Options

Cosentyx's pricing has raised concerns among patients and healthcare providers. As a result, patients may be interested in researching alternative biologics, such as Taltz (ixekizumab) or Stelara (ustekinumab).

References:

[1] Data on file with Novartis Pharmaceuticals Corporation (2018)
[2] ClinicalTrials.gov (NCT01443573)
[3] DrugPatentWatch.com (2023)
[4] Cosentyx product monograph (Novartis Pharmaceuticals Corporation, 2022)